From signal to strategy: The future of systemic viral immunotherapy in GI tumors and Oncolytics Biotech

In an increasingly crowded oncology landscape, confidence is built through rigorous science, clinical execution, and a clear development strategy. Join Oncolytics Biotech for an in-depth discussion on systemically delivered viral immunotherapy and how emerging clinical and translational insights for pelareorep are shaping the company’s path forward in gastrointestinal tumors that have historically shown limited efficacy to current immunotherapies.

Featuring leading academic and clinical experts, the conversation will frame recent progress through unmet patient need, platform potential, regulatory clarity, and expedited designations across GI indications that underpin an efficient path toward registration. Panelists will discuss how pelareorep may enable value creation across indications and partnership opportunities as the field advances.